Effect Of Uremic Toxins In Various Clinical Conditions

Kidney International (2001) 59, S271–S277; doi:10.1046/j.1523-1755.2001.59780271.x

Complement components as uremic toxins and their potential role as mediators of microinflammation

REINHOLD M DEPPISCH1, WERNER BECK1, HERMANN GOEHL1 and EBERHARD RITZ1

1Gambro Corporate Research, Hechingen, and Department of Internal Medicine, Ruperto Carola University Heidelberg, Heidelberg, Germany

Correspondence: Reinhold M. Deppisch, Ph.D., Gambro Corporate Research, 72379 Hechingen, Germany. E-mail: reinhold.deppisch@gambro.com

Top

Abstract

Complement components as uremic toxins and their potential role as mediators of microinflammation. Cardiovascular disease is the major cause of death in end-stage renal disease (ESRD) patients. There is growing evidence that atherogenesis is an inflammatory rather than a purely degenerative process leading to a state of microinflammation. This raises the issue of whether treatment modalities of ESRD contribute to the microinflammatory state. One potential candidate in this context is the complement system. Here we consider three potential pathways linking complement activation to progression of atherosclerosis: (1) complement activation on artificial surfaces depends on their physicochemical characteristics, the effect of which is amplified because of the accumulation of complement factor D; (2) the exposure of ESRD patients to endotoxin creates a microinflammatory state, and this may amplify complement-induced damage; exposure to endotoxin may result from frequent infections because of the impairment of host-defense mechanisms or from transfer of bacterial contaminants across dialysis membranes into the blood stream; and (3) direct transduction of proinflammatory signals from blood-material interactions to the vascular system. We conclude that the complement system is an important candidate system in the genesis of microinflammation and accelerated atherogenesis in ESRD. We advance the hypothesis that the generation of proinflammatory signals, in which the complement system appears to be involved—both through systemic and local activation—plays a role in the development of late complications of uremia, including coronary heart disease. This hypothesis provides a rationale to maximize the biocompatibility of the dialysis procedure, that is, selection of nonactivating materials, use of ultrapure dialysis fluid, and—still theoretical—high-flux dialysis to remove factor D.

Keywords:

inflammation, factor D, vascular damage, atherosclerosis, hemodialysis, biocompatibility

Top

References

References

1. Excerpts from United States Renal Data System 1999 Annual Data Report.Am J Kidney Dis 1999; 34 Suppl 1: S1–S176. | ISI |
2. TSAKIRIS D, JONES EHP, BRIGGS D, ELINDER CG, MEHLS O, MENDEL S, PICCOLI G, RIGDEN SPA, PINTOS DOS SANTOS J, SIMPSON K & VANRENTERGHEM Y. Deaths within 90 days from starting renal replacement therapy in the ERA-EDTA Registry between 1990 and 1992. Nephrol Dial Transplant 1999; 14: 2343–2350. | PubMed |
3. ROSS FH. Atherosclerosis: An inflammatory disease. N Engl J Med 1999; 340: 115–126. | Article | PubMed | ISI | ChemPort |
4. ZIMMERMANN J, HERRLINGER S, PRUY A, METZGER T & WANNER C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648–658. | PubMed |
5. ISEKI K, TOZAWA M, YOSHI S & FUKIYAMA K. Serum C-reactive protein (CRP) and risk of death in chronic dialysis. Nephrol Dial Transplant 1999; 14: 1956–1960. | PubMed | ISI | ChemPort |
6. LIUZZO G, BIASUCCI LM, GALLIMORE JR, GRILLO RL, REBUZZI AG, PEPYS MB & MASERI A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 417–424. | Article | PubMed | ISI | ChemPort |
7. RIDKER PM, CUSHMAN M, STAMPEER MJ, TRACY RP & HENNEKENS CH. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–979. | Article | PubMed | ISI | ChemPort |
8. RIDKER PM, BURING JE, SHIH J, MATIAS M & HENNEKENS CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1999; 98: 731–733.
9. STENVINKEL P, HEIMBÜRGER O, PAULTRE F, DICZFALUSY U, WANG T, BERGLUND L & JOGESTRAND T. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899–1911. | PubMed |
10. BERGSTRÖM J & LINDHOLM B. Malnutrition, cardiac disease, and mortality: An integrated point of view. Am J Kidney Dis 1998; 32: 834–841. | PubMed | ISI | ChemPort |
11. HAENSCH GM. Interaction with effector cells. inThe Complement System 1998; edited by ROTHER, K, TILL, GO, HAENSCH, GM Heidelberg, Springer pp 260–278.
12. ROTHER K, TILL GO & HAENSCH GM. The Complement System 1998; Heidelberg, Springer.
13. MATHIESON PW. Is complement a target for therapy in renal disease?. Kidney Int 1998; 54: 1429–1436. | Article | PubMed |
14. DEPPISCH R, GÖHL H, RITZ E & HÄNSCH GM. Complement activation of artificial surfaces in biomedical therapies. inThe Complement System 1998; edited by ROTHER, K. TILL, GO, HAENSCH, GM Heidelberg, Springer pp 487–504.
15. SEIFERT PS, MESSNER M, ROTH I & BHAKDI S. Analysis of complement C3 activation products in human atherosclerotic lesions. Atherosclerosis 1991; 91: 155–162. | PubMed |
16. PANGBURN MK. Alternative pathway: Activation and regulation. inThe Complement System 1998; edited by ROTHER, K, TILL, GO, HAENSCH, GM Heidelberg, Springer pp 93–115.
17. REID KBM. Lectin pathway of non-self recognition. inThe Complement System 1998; edited by ROTHER, K, TILL, GO, HAENSCH, GM Heidelberg, Springer pp 86–92.
18. DEPPISCH R, SCHMITT V, BOMMER J, HÄNSCH GM, RITZ E & RAUTERBERG EW. Fluid phase generation of terminal complement complex as a novel index of bioincompatibility. Kidney Int 1990; 37: 696–706. | PubMed | ISI | ChemPort |
19. OPPERMANN M, KURTZ C, ZIERS R, QUENTIN E, WEBER MH & GÖTZE O. Elevated plasma levels of the immunosuppressive complement: Fragment Ba in renal failure. Kidney Int 1991; 40: 939–947. | PubMed |
20. GABAY C & KUSHNER I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448–454. | Article | PubMed | ISI | ChemPort |
21. DEPPISCH R, RITZ E, HANSCH GM, SCHÖLS M & RAUTERBERG EW. Bioincompatibility: Perspectives in 1993. Kidney Int 1994; 45: S77–S84. | ISI |
22. DEPPISCH R, GOHL H & SMEBY L. Microdomain structure of polymeric surfaces: Potential for improving blood treatment procedures. Nephrol Dial Transplant 1998; 13: 1354–1359. | PubMed | ISI | ChemPort |
23. SCHINDLER R, LINNENWEBER S, SCHULZE M, OPPERMANN M, DINARELLO CA, SHALDON S & KOCH KM. Gene expression of interleukin-1beta during hemodialysis. Kidney Int 1993; 43: 712–721. | PubMed | ISI | ChemPort |
24. RINDER CS, RINDER HM, SMITH BR, FITCH JC, SMITH MJ, TRACEY JB, MATIS LA, SQUINTO SP & ROLLINS SA. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 1995; 96: 1564–1572. | PubMed |
25. HAAG-WEBER M, MAI B, DEPPISCH R, GOHL H & HÖRL WH. Studies of biocompatibility of different dialyzer membranes: Role of complement system, intracellular calcium and inositol-triphosphate. Clin Nephrol 1994; 41: 245–251. | PubMed |
26. PASCUAL M, STEIGER G, ESTREICHER J, MACON K, VOLANAKIS JE & SCHIFFERLI JA. Metabolism of complement factor D in renal failure. Kidney Int 1988; 34: 529–536. | PubMed | ISI | ChemPort |
27. BALKE N, HOLTKAMP U, HÖRL WH & TSCHESCHE H. Inhibition of degranulation of human polymorphonuclear leukocytes by complement factor D. FEBS Lett 1995; 371: 300–302. | PubMed |
28. KAISER JP, OPPERMANN M, GÖTZE O, DEPPISCH R, GÖHL H, ASMUS G, RÖHRICH B, VON HERRATH D & SCHAEFER K. Significant reduction of factor D and immunosuppressive complement fragment Ba by hemofiltration. Blood Purif 1995; 13: 314–321. | PubMed | ISI | ChemPort |
29. COMBE C, POURTEIN M, DE PRÉCIGOUT V, BAQUEY A, MOREL D, POTAUX L, VINCENDEAU P, BEZIAN JH & APARICIO M. Granulocyte activation and adhesion molecules during hemodialysis with cuprophane and a high-flux biocompatible membrane. Am J Kidney Dis 1994; 24: 437–442. | PubMed |
30. KASSIRER M, ZELTSER D, PROCHOROV V, SCHOENMAN G, FRIMERMAN A, KEREN G, SHAPIRA I, MILLER H, ROTH A, ARBER N, ELDOR A & BERLINER S. Increased expression of the CD11b/CD18 antigen on the surface of peripheral white blood cells in patients with ischemic heart disease: Further evidence for smoldering inflammation in patients with atherosclerosis. Am Heart J 1999; 138: 555–559. | PubMed |
31. DEPPISCH R, HAUG U, GÖHL H & RITZ E. Role of proteinase/antiproteinase disequilibrium in the bioincompatibility induced by artificial surfaces. Nephrol Dial Transplant 1994; Suppl 3 17–23.
32. LONNEMANN G, BEHME TC, LENZNER B, FLOEGE J, SCHULZE M, COLTON CK, KOCH KM & SHALDON S. Permeability of dialyzer membranes to TNFalpha-inducing substances derived from water bacteria. Kidney Int 1992; 42: 61–68. | PubMed | ISI | ChemPort |
33. DESCAMPS-LATSCHA B. The immune system in end-stage renal disease. Curr Opin Nephrol Hypertens 1993; 2: 883–891. | PubMed | ChemPort |
34. HAAG-WEBER M, MAI B & HÖRL WH. Isolation of a granulocyte inhibitory protein from uraemic patients with homology of beta2-microglobulin. Nephrol Dial Transplant 1994; 9: 382–388. | PubMed | ChemPort |
35. HÖRL WH. Genesis of the uraemic syndrome: Role of uraemic toxins. Wien Klin Wochenschr 1998; 110: 511–520. | PubMed |
36. MOLD C, RODGERS CP, KAPLAN RL & GEWURZ H. Binding of human C-reactive protein to bacteria. Infect Immun 1982; 38: 392–395. | PubMed |
37. HOLZER TJ, EDWARDS KM, GEWURZ H & MOLD C. Binding of C-reactive protein to the pneumococcal capsule or cell wall results in differential localization of C3 and stimulation of phagocytosis. J Immunol 1984; 133: 1424–1430. | PubMed |
38. JONES SA, NOVICK D, HORIUCHI S, YAMAMOTO N, SZALAI AJ & FULLER GM. C-reactive protein: A physiological activator of interleukin 6 receptor shedding. J Exp Med 1999; 189: 599–604. | Article | PubMed | ISI | ChemPort |
39. SCHALKWIJK CG, POLAND DCW, VAN DIJK W, KOK A, EMEIS JJ, DRÄGER AM, DONI A, VAN HINSBERGH VWM & STEHOUWER CDA. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlated with markers of endothelial dysfunction: Evidence for chronic inflammation. Diabetologia 1999; 42: 351–357. | Article | PubMed | ISI | ChemPort |
40. BETZ M, HANSCH GM, RAUTERBERG E-W, BOMMER J & RITZ E. Cuprammonium membranes stimulate interleukin 1 release and arachidonic acid metabolism in monocytes in the absence of complement. Kidney Int 1988; 34: 67–73. | PubMed |
41. MCINTYRE C, HARPER I, MACDOUGALL IC, RAINE AE, WILLIAMS A & BAKER LR. Serum C-reactive protein as a marker for infection and inflammation in regular dialysis patients. Clin Nephrol 1997; 48: 371–374. | PubMed | ISI | ChemPort |
42. VOLANAKIS JE. Transcriptional regulation of complement genes. Annu Rev Immunol 1995; 13: 277–305. | PubMed |
43. RAMADORI G, RASOKAT H, BURGER R, MEYER ZUM BUSCHENFELDE KH & BITTER-SUERMANN D. Quantitative determination of complement components produced by purified hepatocytes. Clin Exp Immunol 1984; 55: 189–196. | PubMed |
44. OPPENHEIM JJ, KUSHNER I, SEDOR JR & JABER BL. Basic science for nephrologists: Uremia: An inflammatory process. Syllabus Clinical Nephrology Symposia 1999; Miami, American Society of Nephrology p 3374.
45. VOLANAKIS JE. Complement activation by C-reactive protein complexes. Ann NY Acad Sci 1982; 389: 235–250. | PubMed | ChemPort |
46. PANG AS, KATZ A & MINTA JO. C3 deposition in cholesterol-induced atherosclerosis in rabbits: A possible etiologic role for complement in atherogenesis. J Immunol 1979; 123: 1117–1122. | PubMed |
47. VLAICU R, NICULESCU F, RUS HG & CRISTEA A. Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis 1985; 57: 163–177. | PubMed | ISI | ChemPort |
48. SEIFERT PS, HUGO F, TRANUM-JENSEN J, ZAHRINGER U, MUHLY M & BHAKDI S. Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J Exp Med 1990; 172: 547–557. | Article | PubMed | ISI | ChemPort |
49. TORZEWSKI J, OLDROYD R, LACHMANN P, FITZSIMMONS C, PROUDFOOT D & BOWYER D. Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. Arterioscler Thromb Vasc Biol 1996; 16: 673–677. | PubMed |
50. TORZEWSKI J, TORZEWSKI M, BOWYER DE, FRÖHLICH M, KOENIG W, WALTENBERGER J, FITZSIMMONS C & HOMBACH V. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998; 18: 1386–1392. | PubMed | ISI | ChemPort |
51. HORI Y. Crry, a complement regulatory protein, modulates renal interstitial disease induced by proteinuria 1. Kidney Int 1999; 56: 2096–2106. | PubMed |
52. TEDESCO F, FISCHETTI F, PAUSA M, DOBRINA A, SIM RB & DAHA MR. Complement-endothelial cell interactions: Pathophysiological implications. Mol Immunol 1999; 36: 261–268. | PubMed |
53. ACOSTA J, HETTINGA J, FLUCKIGER R, KRUMREI N, GOLDFINE A, ANGARITA L & HALPERIN J. Molecular basis for a link between complement and the vascular complications of diabetes. Proc Natl Acad Sci USA 2000; 97: 5450–5455. | PubMed |

Extra navigation

.
ADVERTISEMENT